nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00192	0.00311	CcSEcCtD
Paliperidone—Lethargy—Capecitabine—esophageal cancer	0.00192	0.00311	CcSEcCtD
Paliperidone—Conjunctivitis—Cisplatin—esophageal cancer	0.00191	0.0031	CcSEcCtD
Paliperidone—Cystitis noninfective—Methotrexate—esophageal cancer	0.00188	0.00305	CcSEcCtD
Paliperidone—Pain in extremity—Capecitabine—esophageal cancer	0.00188	0.00305	CcSEcCtD
Paliperidone—Osteoarthritis—Capecitabine—esophageal cancer	0.00188	0.00305	CcSEcCtD
Paliperidone—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00186	0.00302	CcSEcCtD
Paliperidone—Cystitis—Methotrexate—esophageal cancer	0.00186	0.00302	CcSEcCtD
Paliperidone—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00186	0.00302	CcSEcCtD
Paliperidone—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00186	0.00301	CcSEcCtD
Paliperidone—Face oedema—Capecitabine—esophageal cancer	0.00181	0.00294	CcSEcCtD
Paliperidone—Bradycardia—Cisplatin—esophageal cancer	0.0018	0.00291	CcSEcCtD
Paliperidone—Urinary retention—Capecitabine—esophageal cancer	0.00179	0.0029	CcSEcCtD
Paliperidone—Cardiac arrest—Capecitabine—esophageal cancer	0.00179	0.0029	CcSEcCtD
Paliperidone—Bladder pain—Methotrexate—esophageal cancer	0.00174	0.00283	CcSEcCtD
Paliperidone—Urinary tract disorder—Cisplatin—esophageal cancer	0.00174	0.00282	CcSEcCtD
Paliperidone—Connective tissue disorder—Cisplatin—esophageal cancer	0.00173	0.00281	CcSEcCtD
Paliperidone—Urethral disorder—Cisplatin—esophageal cancer	0.00173	0.0028	CcSEcCtD
Paliperidone—Gynaecomastia—Methotrexate—esophageal cancer	0.00172	0.0028	CcSEcCtD
Paliperidone—Dry skin—Capecitabine—esophageal cancer	0.00172	0.00279	CcSEcCtD
Paliperidone—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00172	0.00278	CcSEcCtD
Paliperidone—Abdominal pain upper—Capecitabine—esophageal cancer	0.00172	0.00278	CcSEcCtD
Paliperidone—Breast disorder—Capecitabine—esophageal cancer	0.0017	0.00275	CcSEcCtD
Paliperidone—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00169	0.00274	CcSEcCtD
Paliperidone—Nasopharyngitis—Capecitabine—esophageal cancer	0.00168	0.00272	CcSEcCtD
Paliperidone—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00166	0.00269	CcSEcCtD
Paliperidone—Muscular weakness—Capecitabine—esophageal cancer	0.00166	0.00269	CcSEcCtD
Paliperidone—Eye disorder—Cisplatin—esophageal cancer	0.00165	0.00267	CcSEcCtD
Paliperidone—Tinnitus—Cisplatin—esophageal cancer	0.00164	0.00267	CcSEcCtD
Paliperidone—Cardiac disorder—Cisplatin—esophageal cancer	0.00164	0.00265	CcSEcCtD
Paliperidone—Flushing—Cisplatin—esophageal cancer	0.00164	0.00265	CcSEcCtD
Paliperidone—Influenza—Capecitabine—esophageal cancer	0.00162	0.00263	CcSEcCtD
Paliperidone—Dysphagia—Capecitabine—esophageal cancer	0.00162	0.00263	CcSEcCtD
Paliperidone—Diabetes mellitus—Methotrexate—esophageal cancer	0.00161	0.00261	CcSEcCtD
Paliperidone—Immune system disorder—Cisplatin—esophageal cancer	0.00159	0.00258	CcSEcCtD
Paliperidone—Mediastinal disorder—Cisplatin—esophageal cancer	0.00159	0.00258	CcSEcCtD
Paliperidone—Bronchitis—Capecitabine—esophageal cancer	0.00156	0.00253	CcSEcCtD
Paliperidone—Alopecia—Cisplatin—esophageal cancer	0.00156	0.00253	CcSEcCtD
Paliperidone—Abdominal discomfort—Capecitabine—esophageal cancer	0.00156	0.00252	CcSEcCtD
Paliperidone—Erythema—Cisplatin—esophageal cancer	0.00154	0.00249	CcSEcCtD
Paliperidone—Malnutrition—Cisplatin—esophageal cancer	0.00154	0.00249	CcSEcCtD
Paliperidone—Dysuria—Capecitabine—esophageal cancer	0.00152	0.00246	CcSEcCtD
Paliperidone—Neutropenia—Capecitabine—esophageal cancer	0.00152	0.00246	CcSEcCtD
Paliperidone—Flatulence—Cisplatin—esophageal cancer	0.00151	0.00245	CcSEcCtD
Paliperidone—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00151	0.00245	CcSEcCtD
Paliperidone—Weight increased—Capecitabine—esophageal cancer	0.00148	0.0024	CcSEcCtD
Paliperidone—Muscle spasms—Cisplatin—esophageal cancer	0.00148	0.00239	CcSEcCtD
Paliperidone—Weight decreased—Capecitabine—esophageal cancer	0.00147	0.00238	CcSEcCtD
Paliperidone—Hyperglycaemia—Capecitabine—esophageal cancer	0.00147	0.00238	CcSEcCtD
Paliperidone—Pneumonia—Capecitabine—esophageal cancer	0.00146	0.00236	CcSEcCtD
Paliperidone—Infestation NOS—Capecitabine—esophageal cancer	0.00145	0.00235	CcSEcCtD
Paliperidone—Infestation—Capecitabine—esophageal cancer	0.00145	0.00235	CcSEcCtD
Paliperidone—Vision blurred—Cisplatin—esophageal cancer	0.00145	0.00235	CcSEcCtD
Paliperidone—Depression—Capecitabine—esophageal cancer	0.00144	0.00234	CcSEcCtD
Paliperidone—Tremor—Cisplatin—esophageal cancer	0.00144	0.00233	CcSEcCtD
Paliperidone—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00143	0.00231	CcSEcCtD
Paliperidone—Lethargy—Methotrexate—esophageal cancer	0.00143	0.00231	CcSEcCtD
Paliperidone—Ill-defined disorder—Cisplatin—esophageal cancer	0.00142	0.00231	CcSEcCtD
Paliperidone—Anaemia—Cisplatin—esophageal cancer	0.00142	0.0023	CcSEcCtD
Paliperidone—Jaundice—Capecitabine—esophageal cancer	0.00141	0.00229	CcSEcCtD
Paliperidone—Conjunctivitis—Capecitabine—esophageal cancer	0.00141	0.00228	CcSEcCtD
Paliperidone—Urinary tract infection—Capecitabine—esophageal cancer	0.00141	0.00228	CcSEcCtD
Paliperidone—Osteoarthritis—Methotrexate—esophageal cancer	0.0014	0.00227	CcSEcCtD
Paliperidone—Malaise—Cisplatin—esophageal cancer	0.00138	0.00224	CcSEcCtD
Paliperidone—Leukopenia—Cisplatin—esophageal cancer	0.00137	0.00223	CcSEcCtD
Paliperidone—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00137	0.00222	CcSEcCtD
Paliperidone—Epistaxis—Capecitabine—esophageal cancer	0.00137	0.00221	CcSEcCtD
Paliperidone—Agranulocytosis—Capecitabine—esophageal cancer	0.00135	0.00219	CcSEcCtD
Paliperidone—Convulsion—Cisplatin—esophageal cancer	0.00133	0.00216	CcSEcCtD
Paliperidone—Bradycardia—Capecitabine—esophageal cancer	0.00132	0.00215	CcSEcCtD
Paliperidone—Myalgia—Cisplatin—esophageal cancer	0.00131	0.00212	CcSEcCtD
Paliperidone—Rhinitis—Capecitabine—esophageal cancer	0.0013	0.00211	CcSEcCtD
Paliperidone—Anxiety—Cisplatin—esophageal cancer	0.0013	0.00211	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.0013	0.0021	CcSEcCtD
Paliperidone—Hypoaesthesia—Capecitabine—esophageal cancer	0.00129	0.0021	CcSEcCtD
Paliperidone—Discomfort—Cisplatin—esophageal cancer	0.00129	0.00209	CcSEcCtD
Paliperidone—Urinary tract disorder—Capecitabine—esophageal cancer	0.00128	0.00208	CcSEcCtD
Paliperidone—Oedema peripheral—Capecitabine—esophageal cancer	0.00128	0.00208	CcSEcCtD
Paliperidone—Connective tissue disorder—Capecitabine—esophageal cancer	0.00128	0.00207	CcSEcCtD
Paliperidone—Urethral disorder—Capecitabine—esophageal cancer	0.00127	0.00207	CcSEcCtD
Paliperidone—Breast disorder—Methotrexate—esophageal cancer	0.00126	0.00205	CcSEcCtD
Paliperidone—Anaphylactic shock—Cisplatin—esophageal cancer	0.00125	0.00203	CcSEcCtD
Paliperidone—Oedema—Cisplatin—esophageal cancer	0.00125	0.00203	CcSEcCtD
Paliperidone—Infection—Cisplatin—esophageal cancer	0.00125	0.00202	CcSEcCtD
Paliperidone—Nervous system disorder—Cisplatin—esophageal cancer	0.00123	0.00199	CcSEcCtD
Paliperidone—Thrombocytopenia—Cisplatin—esophageal cancer	0.00123	0.00199	CcSEcCtD
Paliperidone—Tachycardia—Cisplatin—esophageal cancer	0.00122	0.00198	CcSEcCtD
Paliperidone—Skin disorder—Cisplatin—esophageal cancer	0.00122	0.00197	CcSEcCtD
Paliperidone—Eye disorder—Capecitabine—esophageal cancer	0.00122	0.00197	CcSEcCtD
Paliperidone—Tinnitus—Capecitabine—esophageal cancer	0.00121	0.00197	CcSEcCtD
Paliperidone—Cardiac disorder—Capecitabine—esophageal cancer	0.00121	0.00196	CcSEcCtD
Paliperidone—Flushing—Capecitabine—esophageal cancer	0.00121	0.00196	CcSEcCtD
Paliperidone—Anorexia—Cisplatin—esophageal cancer	0.00119	0.00194	CcSEcCtD
Paliperidone—Pancreatitis—Methotrexate—esophageal cancer	0.00119	0.00192	CcSEcCtD
Paliperidone—Angiopathy—Capecitabine—esophageal cancer	0.00118	0.00191	CcSEcCtD
Paliperidone—Immune system disorder—Capecitabine—esophageal cancer	0.00117	0.0019	CcSEcCtD
Paliperidone—Mediastinal disorder—Capecitabine—esophageal cancer	0.00117	0.0019	CcSEcCtD
Paliperidone—Hypotension—Cisplatin—esophageal cancer	0.00117	0.0019	CcSEcCtD
Paliperidone—Chills—Capecitabine—esophageal cancer	0.00117	0.00189	CcSEcCtD
Paliperidone—Abdominal discomfort—Methotrexate—esophageal cancer	0.00116	0.00188	CcSEcCtD
Paliperidone—Alopecia—Capecitabine—esophageal cancer	0.00115	0.00186	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00114	0.00185	CcSEcCtD
Paliperidone—Mental disorder—Capecitabine—esophageal cancer	0.00114	0.00185	CcSEcCtD
Paliperidone—Erythema—Capecitabine—esophageal cancer	0.00113	0.00183	CcSEcCtD
Paliperidone—Malnutrition—Capecitabine—esophageal cancer	0.00113	0.00183	CcSEcCtD
Paliperidone—Neutropenia—Methotrexate—esophageal cancer	0.00113	0.00183	CcSEcCtD
Paliperidone—Dysuria—Methotrexate—esophageal cancer	0.00113	0.00183	CcSEcCtD
Paliperidone—Paraesthesia—Cisplatin—esophageal cancer	0.00113	0.00182	CcSEcCtD
Paliperidone—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00112	0.00182	CcSEcCtD
Paliperidone—Dyspnoea—Cisplatin—esophageal cancer	0.00112	0.00181	CcSEcCtD
Paliperidone—Flatulence—Capecitabine—esophageal cancer	0.00112	0.00181	CcSEcCtD
Paliperidone—Erectile dysfunction—Methotrexate—esophageal cancer	0.00111	0.00181	CcSEcCtD
Paliperidone—Dysgeusia—Capecitabine—esophageal cancer	0.00111	0.0018	CcSEcCtD
Paliperidone—Back pain—Capecitabine—esophageal cancer	0.0011	0.00177	CcSEcCtD
Paliperidone—Decreased appetite—Cisplatin—esophageal cancer	0.00109	0.00177	CcSEcCtD
Paliperidone—Muscle spasms—Capecitabine—esophageal cancer	0.00109	0.00176	CcSEcCtD
Paliperidone—Pneumonia—Methotrexate—esophageal cancer	0.00108	0.00176	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00108	0.00175	CcSEcCtD
Paliperidone—Infestation NOS—Methotrexate—esophageal cancer	0.00108	0.00175	CcSEcCtD
Paliperidone—Infestation—Methotrexate—esophageal cancer	0.00108	0.00175	CcSEcCtD
Paliperidone—Depression—Methotrexate—esophageal cancer	0.00108	0.00174	CcSEcCtD
Paliperidone—Pain—Cisplatin—esophageal cancer	0.00107	0.00174	CcSEcCtD
Paliperidone—Vision blurred—Capecitabine—esophageal cancer	0.00107	0.00173	CcSEcCtD
Paliperidone—Tremor—Capecitabine—esophageal cancer	0.00106	0.00172	CcSEcCtD
Paliperidone—Ill-defined disorder—Capecitabine—esophageal cancer	0.00105	0.0017	CcSEcCtD
Paliperidone—Conjunctivitis—Methotrexate—esophageal cancer	0.00105	0.0017	CcSEcCtD
Paliperidone—Anaemia—Capecitabine—esophageal cancer	0.00105	0.0017	CcSEcCtD
Paliperidone—Feeling abnormal—Cisplatin—esophageal cancer	0.00103	0.00167	CcSEcCtD
Paliperidone—Malaise—Capecitabine—esophageal cancer	0.00102	0.00165	CcSEcCtD
Paliperidone—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00102	0.00165	CcSEcCtD
Paliperidone—Epistaxis—Methotrexate—esophageal cancer	0.00102	0.00165	CcSEcCtD
Paliperidone—Vertigo—Capecitabine—esophageal cancer	0.00102	0.00165	CcSEcCtD
Paliperidone—Syncope—Capecitabine—esophageal cancer	0.00102	0.00165	CcSEcCtD
Paliperidone—Leukopenia—Capecitabine—esophageal cancer	0.00101	0.00164	CcSEcCtD
Paliperidone—Agranulocytosis—Methotrexate—esophageal cancer	0.00101	0.00163	CcSEcCtD
Paliperidone—Palpitations—Capecitabine—esophageal cancer	0.001	0.00162	CcSEcCtD
Paliperidone—Loss of consciousness—Capecitabine—esophageal cancer	0.000995	0.00161	CcSEcCtD
Paliperidone—Body temperature increased—Cisplatin—esophageal cancer	0.000991	0.00161	CcSEcCtD
Paliperidone—Cough—Capecitabine—esophageal cancer	0.000988	0.0016	CcSEcCtD
Paliperidone—Hypertension—Capecitabine—esophageal cancer	0.000977	0.00158	CcSEcCtD
Paliperidone—Arthralgia—Capecitabine—esophageal cancer	0.000964	0.00156	CcSEcCtD
Paliperidone—Chest pain—Capecitabine—esophageal cancer	0.000964	0.00156	CcSEcCtD
Paliperidone—Myalgia—Capecitabine—esophageal cancer	0.000964	0.00156	CcSEcCtD
Paliperidone—Anxiety—Capecitabine—esophageal cancer	0.00096	0.00156	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000957	0.00155	CcSEcCtD
Paliperidone—Urinary tract disorder—Methotrexate—esophageal cancer	0.000956	0.00155	CcSEcCtD
Paliperidone—Discomfort—Capecitabine—esophageal cancer	0.000952	0.00154	CcSEcCtD
Paliperidone—Urethral disorder—Methotrexate—esophageal cancer	0.000949	0.00154	CcSEcCtD
Paliperidone—Dry mouth—Capecitabine—esophageal cancer	0.000943	0.00153	CcSEcCtD
Paliperidone—Confusional state—Capecitabine—esophageal cancer	0.000932	0.00151	CcSEcCtD
Paliperidone—Oedema—Capecitabine—esophageal cancer	0.000924	0.0015	CcSEcCtD
Paliperidone—Hypersensitivity—Cisplatin—esophageal cancer	0.000923	0.0015	CcSEcCtD
Paliperidone—Infection—Capecitabine—esophageal cancer	0.000918	0.00149	CcSEcCtD
Paliperidone—Shock—Capecitabine—esophageal cancer	0.000909	0.00147	CcSEcCtD
Paliperidone—Nervous system disorder—Capecitabine—esophageal cancer	0.000906	0.00147	CcSEcCtD
Paliperidone—Eye disorder—Methotrexate—esophageal cancer	0.000905	0.00147	CcSEcCtD
Paliperidone—Thrombocytopenia—Capecitabine—esophageal cancer	0.000905	0.00147	CcSEcCtD
Paliperidone—Tinnitus—Methotrexate—esophageal cancer	0.000903	0.00146	CcSEcCtD
Paliperidone—Tachycardia—Capecitabine—esophageal cancer	0.000902	0.00146	CcSEcCtD
Paliperidone—Asthenia—Cisplatin—esophageal cancer	0.000899	0.00146	CcSEcCtD
Paliperidone—Cardiac disorder—Methotrexate—esophageal cancer	0.000898	0.00146	CcSEcCtD
Paliperidone—Skin disorder—Capecitabine—esophageal cancer	0.000897	0.00145	CcSEcCtD
Paliperidone—Anorexia—Capecitabine—esophageal cancer	0.000881	0.00143	CcSEcCtD
Paliperidone—Angiopathy—Methotrexate—esophageal cancer	0.000878	0.00142	CcSEcCtD
Paliperidone—Immune system disorder—Methotrexate—esophageal cancer	0.000874	0.00142	CcSEcCtD
Paliperidone—Mediastinal disorder—Methotrexate—esophageal cancer	0.000873	0.00141	CcSEcCtD
Paliperidone—Chills—Methotrexate—esophageal cancer	0.000869	0.00141	CcSEcCtD
Paliperidone—Hypotension—Capecitabine—esophageal cancer	0.000863	0.0014	CcSEcCtD
Paliperidone—Diarrhoea—Cisplatin—esophageal cancer	0.000858	0.00139	CcSEcCtD
Paliperidone—Alopecia—Methotrexate—esophageal cancer	0.000855	0.00139	CcSEcCtD
Paliperidone—Mental disorder—Methotrexate—esophageal cancer	0.000848	0.00137	CcSEcCtD
Paliperidone—Erythema—Methotrexate—esophageal cancer	0.000843	0.00137	CcSEcCtD
Paliperidone—Malnutrition—Methotrexate—esophageal cancer	0.000843	0.00137	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000842	0.00136	CcSEcCtD
Paliperidone—Insomnia—Capecitabine—esophageal cancer	0.000836	0.00135	CcSEcCtD
Paliperidone—Paraesthesia—Capecitabine—esophageal cancer	0.00083	0.00134	CcSEcCtD
Paliperidone—Dysgeusia—Methotrexate—esophageal cancer	0.000825	0.00134	CcSEcCtD
Paliperidone—Dyspnoea—Capecitabine—esophageal cancer	0.000824	0.00134	CcSEcCtD
Paliperidone—Back pain—Methotrexate—esophageal cancer	0.000815	0.00132	CcSEcCtD
Paliperidone—Dyspepsia—Capecitabine—esophageal cancer	0.000813	0.00132	CcSEcCtD
Paliperidone—Decreased appetite—Capecitabine—esophageal cancer	0.000803	0.0013	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000798	0.00129	CcSEcCtD
Paliperidone—Vomiting—Cisplatin—esophageal cancer	0.000797	0.00129	CcSEcCtD
Paliperidone—Fatigue—Capecitabine—esophageal cancer	0.000797	0.00129	CcSEcCtD
Paliperidone—Vision blurred—Methotrexate—esophageal cancer	0.000794	0.00129	CcSEcCtD
Paliperidone—Rash—Cisplatin—esophageal cancer	0.00079	0.00128	CcSEcCtD
Paliperidone—Pain—Capecitabine—esophageal cancer	0.00079	0.00128	CcSEcCtD
Paliperidone—Constipation—Capecitabine—esophageal cancer	0.00079	0.00128	CcSEcCtD
Paliperidone—Dermatitis—Cisplatin—esophageal cancer	0.00079	0.00128	CcSEcCtD
Paliperidone—Ill-defined disorder—Methotrexate—esophageal cancer	0.000782	0.00127	CcSEcCtD
Paliperidone—Anaemia—Methotrexate—esophageal cancer	0.000779	0.00126	CcSEcCtD
Paliperidone—Feeling abnormal—Capecitabine—esophageal cancer	0.000761	0.00123	CcSEcCtD
Paliperidone—Malaise—Methotrexate—esophageal cancer	0.00076	0.00123	CcSEcCtD
Paliperidone—Vertigo—Methotrexate—esophageal cancer	0.000757	0.00123	CcSEcCtD
Paliperidone—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000756	0.00122	CcSEcCtD
Paliperidone—Leukopenia—Methotrexate—esophageal cancer	0.000754	0.00122	CcSEcCtD
Paliperidone—Nausea—Cisplatin—esophageal cancer	0.000745	0.00121	CcSEcCtD
Paliperidone—Cough—Methotrexate—esophageal cancer	0.000735	0.00119	CcSEcCtD
Paliperidone—Urticaria—Capecitabine—esophageal cancer	0.000734	0.00119	CcSEcCtD
Paliperidone—Body temperature increased—Capecitabine—esophageal cancer	0.00073	0.00118	CcSEcCtD
Paliperidone—Abdominal pain—Capecitabine—esophageal cancer	0.00073	0.00118	CcSEcCtD
Paliperidone—Convulsion—Methotrexate—esophageal cancer	0.00073	0.00118	CcSEcCtD
Paliperidone—Myalgia—Methotrexate—esophageal cancer	0.000717	0.00116	CcSEcCtD
Paliperidone—Arthralgia—Methotrexate—esophageal cancer	0.000717	0.00116	CcSEcCtD
Paliperidone—Chest pain—Methotrexate—esophageal cancer	0.000717	0.00116	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000713	0.00115	CcSEcCtD
Paliperidone—Discomfort—Methotrexate—esophageal cancer	0.000709	0.00115	CcSEcCtD
Paliperidone—Confusional state—Methotrexate—esophageal cancer	0.000694	0.00112	CcSEcCtD
Paliperidone—Anaphylactic shock—Methotrexate—esophageal cancer	0.000688	0.00111	CcSEcCtD
Paliperidone—Infection—Methotrexate—esophageal cancer	0.000683	0.00111	CcSEcCtD
Paliperidone—Hypersensitivity—Capecitabine—esophageal cancer	0.000681	0.0011	CcSEcCtD
Paliperidone—Nervous system disorder—Methotrexate—esophageal cancer	0.000675	0.00109	CcSEcCtD
Paliperidone—Thrombocytopenia—Methotrexate—esophageal cancer	0.000673	0.00109	CcSEcCtD
Paliperidone—Skin disorder—Methotrexate—esophageal cancer	0.000668	0.00108	CcSEcCtD
Paliperidone—Asthenia—Capecitabine—esophageal cancer	0.000663	0.00107	CcSEcCtD
Paliperidone—Anorexia—Methotrexate—esophageal cancer	0.000656	0.00106	CcSEcCtD
Paliperidone—Pruritus—Capecitabine—esophageal cancer	0.000654	0.00106	CcSEcCtD
Paliperidone—Hypotension—Methotrexate—esophageal cancer	0.000643	0.00104	CcSEcCtD
Paliperidone—Diarrhoea—Capecitabine—esophageal cancer	0.000632	0.00102	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000627	0.00102	CcSEcCtD
Paliperidone—Insomnia—Methotrexate—esophageal cancer	0.000622	0.00101	CcSEcCtD
Paliperidone—Paraesthesia—Methotrexate—esophageal cancer	0.000618	0.001	CcSEcCtD
Paliperidone—Dyspnoea—Methotrexate—esophageal cancer	0.000613	0.000994	CcSEcCtD
Paliperidone—Somnolence—Methotrexate—esophageal cancer	0.000611	0.000991	CcSEcCtD
Paliperidone—Dizziness—Capecitabine—esophageal cancer	0.000611	0.00099	CcSEcCtD
Paliperidone—Dyspepsia—Methotrexate—esophageal cancer	0.000605	0.000981	CcSEcCtD
Paliperidone—Decreased appetite—Methotrexate—esophageal cancer	0.000598	0.000969	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000594	0.000962	CcSEcCtD
Paliperidone—Fatigue—Methotrexate—esophageal cancer	0.000593	0.000961	CcSEcCtD
Paliperidone—Pain—Methotrexate—esophageal cancer	0.000588	0.000953	CcSEcCtD
Paliperidone—Vomiting—Capecitabine—esophageal cancer	0.000587	0.000952	CcSEcCtD
Paliperidone—Rash—Capecitabine—esophageal cancer	0.000583	0.000944	CcSEcCtD
Paliperidone—Dermatitis—Capecitabine—esophageal cancer	0.000582	0.000943	CcSEcCtD
Paliperidone—Headache—Capecitabine—esophageal cancer	0.000579	0.000938	CcSEcCtD
Paliperidone—Feeling abnormal—Methotrexate—esophageal cancer	0.000567	0.000919	CcSEcCtD
Paliperidone—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000562	0.000912	CcSEcCtD
Paliperidone—Nausea—Capecitabine—esophageal cancer	0.000549	0.00089	CcSEcCtD
Paliperidone—Urticaria—Methotrexate—esophageal cancer	0.000546	0.000886	CcSEcCtD
Paliperidone—Abdominal pain—Methotrexate—esophageal cancer	0.000544	0.000881	CcSEcCtD
Paliperidone—Body temperature increased—Methotrexate—esophageal cancer	0.000544	0.000881	CcSEcCtD
Paliperidone—Hypersensitivity—Methotrexate—esophageal cancer	0.000507	0.000821	CcSEcCtD
Paliperidone—Asthenia—Methotrexate—esophageal cancer	0.000493	0.0008	CcSEcCtD
Paliperidone—Pruritus—Methotrexate—esophageal cancer	0.000487	0.000789	CcSEcCtD
Paliperidone—Diarrhoea—Methotrexate—esophageal cancer	0.000471	0.000763	CcSEcCtD
Paliperidone—Dizziness—Methotrexate—esophageal cancer	0.000455	0.000737	CcSEcCtD
Paliperidone—Vomiting—Methotrexate—esophageal cancer	0.000437	0.000709	CcSEcCtD
Paliperidone—Rash—Methotrexate—esophageal cancer	0.000434	0.000703	CcSEcCtD
Paliperidone—Dermatitis—Methotrexate—esophageal cancer	0.000433	0.000702	CcSEcCtD
Paliperidone—Headache—Methotrexate—esophageal cancer	0.000431	0.000698	CcSEcCtD
Paliperidone—Nausea—Methotrexate—esophageal cancer	0.000409	0.000662	CcSEcCtD
Paliperidone—ADRA2C—Metabolism—CREBBP—esophageal cancer	4.33e-05	0.000113	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—NOS3—esophageal cancer	4.33e-05	0.000113	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—CREBBP—esophageal cancer	4.3e-05	0.000112	CbGpPWpGaD
Paliperidone—HTR1D—Signaling by GPCR—PIK3CA—esophageal cancer	4.28e-05	0.000112	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—EGFR—esophageal cancer	4.28e-05	0.000112	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—NOTCH1—esophageal cancer	4.28e-05	0.000112	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—KDR—esophageal cancer	4.24e-05	0.000111	CbGpPWpGaD
Paliperidone—ADRA2A—Hemostasis—TP53—esophageal cancer	4.23e-05	0.00011	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ALDOB—esophageal cancer	4.23e-05	0.00011	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—EGFR—esophageal cancer	4.22e-05	0.00011	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—ERBB2—esophageal cancer	4.21e-05	0.00011	CbGpPWpGaD
Paliperidone—HTR1B—Signaling by GPCR—PIK3CA—esophageal cancer	4.19e-05	0.000109	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—KDR—esophageal cancer	4.18e-05	0.000109	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CYP1B1—esophageal cancer	4.17e-05	0.000109	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—NOTCH1—esophageal cancer	4.13e-05	0.000108	CbGpPWpGaD
Paliperidone—DRD4—Signaling by GPCR—PIK3CA—esophageal cancer	4.13e-05	0.000108	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—ERBB2—esophageal cancer	4.12e-05	0.000108	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—NOTCH1—esophageal cancer	4.11e-05	0.000107	CbGpPWpGaD
Paliperidone—DRD1—GPCR downstream signaling—PIK3CA—esophageal cancer	4.09e-05	0.000107	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GAPDH—esophageal cancer	4.07e-05	0.000106	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—ERBB2—esophageal cancer	4.05e-05	0.000106	CbGpPWpGaD
Paliperidone—DRD3—GPCR downstream signaling—PIK3CA—esophageal cancer	4.04e-05	0.000105	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CRABP1—esophageal cancer	4.03e-05	0.000105	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—HIF1A—esophageal cancer	4.03e-05	0.000105	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—NOTCH1—esophageal cancer	4e-05	0.000104	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	3.96e-05	0.000103	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—HIF1A—esophageal cancer	3.95e-05	0.000103	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—NOTCH1—esophageal cancer	3.93e-05	0.000103	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CYP19A1—esophageal cancer	3.92e-05	0.000102	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—NOS3—esophageal cancer	3.9e-05	0.000102	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—NOS3—esophageal cancer	3.88e-05	0.000101	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—CREBBP—esophageal cancer	3.88e-05	0.000101	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—HIF1A—esophageal cancer	3.88e-05	0.000101	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—KDR—esophageal cancer	3.85e-05	0.000101	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—NOS3—esophageal cancer	3.85e-05	0.0001	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GNG7—esophageal cancer	3.84e-05	0.0001	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—EGFR—esophageal cancer	3.81e-05	9.95e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—KDR—esophageal cancer	3.79e-05	9.89e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—KDR—esophageal cancer	3.78e-05	9.87e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	3.75e-05	9.78e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	3.73e-05	9.73e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—CCND1—esophageal cancer	3.72e-05	9.7e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—PIK3CA—esophageal cancer	3.71e-05	9.7e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—KDR—esophageal cancer	3.71e-05	9.68e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	3.68e-05	9.61e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—PIK3CA—esophageal cancer	3.67e-05	9.57e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	3.66e-05	9.56e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—ERBB2—esophageal cancer	3.65e-05	9.52e-05	CbGpPWpGaD
Paliperidone—ADRA2B—GPCR downstream signaling—PIK3CA—esophageal cancer	3.64e-05	9.51e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—CCND1—esophageal cancer	3.64e-05	9.5e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	3.63e-05	9.47e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CREBBP—esophageal cancer	3.62e-05	9.46e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	3.6e-05	9.41e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—ERBB2—esophageal cancer	3.6e-05	9.4e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ALDH2—esophageal cancer	3.6e-05	9.39e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—CDKN1A—esophageal cancer	3.59e-05	9.38e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—CCND1—esophageal cancer	3.58e-05	9.35e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—HMOX1—esophageal cancer	3.58e-05	9.34e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	3.57e-05	9.32e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CREBBP—esophageal cancer	3.57e-05	9.31e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—EGFR—esophageal cancer	3.56e-05	9.3e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—NOTCH1—esophageal cancer	3.56e-05	9.3e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—PTGS2—esophageal cancer	3.55e-05	9.27e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—CREBBP—esophageal cancer	3.52e-05	9.19e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—CDKN1A—esophageal cancer	3.52e-05	9.19e-05	CbGpPWpGaD
Paliperidone—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	3.52e-05	9.18e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—EGFR—esophageal cancer	3.51e-05	9.15e-05	CbGpPWpGaD
Paliperidone—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	3.5e-05	9.14e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	3.49e-05	9.12e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—NOS3—esophageal cancer	3.47e-05	9.07e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—CDKN1A—esophageal cancer	3.46e-05	9.04e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—KDR—esophageal cancer	3.45e-05	9e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—ABCB1—esophageal cancer	3.43e-05	8.96e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GSTT1—esophageal cancer	3.42e-05	8.93e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—EP300—esophageal cancer	3.42e-05	8.93e-05	CbGpPWpGaD
Paliperidone—ADRA2C—GPCR downstream signaling—PIK3CA—esophageal cancer	3.4e-05	8.89e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CYP2A6—esophageal cancer	3.38e-05	8.83e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—NOS3—esophageal cancer	3.35e-05	8.76e-05	CbGpPWpGaD
Paliperidone—ADRA1B—GPCR downstream signaling—PIK3CA—esophageal cancer	3.35e-05	8.75e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—EP300—esophageal cancer	3.35e-05	8.74e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—NOS3—esophageal cancer	3.34e-05	8.71e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—PIK3CA—esophageal cancer	3.31e-05	8.64e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—EP300—esophageal cancer	3.3e-05	8.6e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CREBBP—esophageal cancer	3.29e-05	8.59e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—ERBB2—esophageal cancer	3.25e-05	8.48e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	3.25e-05	8.48e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—NOS3—esophageal cancer	3.24e-05	8.47e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	3.24e-05	8.45e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—EGFR—esophageal cancer	3.23e-05	8.44e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CREBBP—esophageal cancer	3.23e-05	8.43e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—CREBBP—esophageal cancer	3.23e-05	8.42e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—CCND1—esophageal cancer	3.22e-05	8.41e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ENO1—esophageal cancer	3.21e-05	8.37e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTGS1—esophageal cancer	3.21e-05	8.37e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	3.19e-05	8.34e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—NOS3—esophageal cancer	3.19e-05	8.34e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—CCND1—esophageal cancer	3.18e-05	8.3e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	3.18e-05	8.3e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	3.18e-05	8.3e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—EGFR—esophageal cancer	3.17e-05	8.28e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	3.17e-05	8.27e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PSME1—esophageal cancer	3.16e-05	8.25e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PSME2—esophageal cancer	3.16e-05	8.25e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—NOS3—esophageal cancer	3.15e-05	8.23e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	3.14e-05	8.19e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	3.12e-05	8.15e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—CDKN1A—esophageal cancer	3.12e-05	8.14e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	3.11e-05	8.13e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—PIK3CA—esophageal cancer	3.09e-05	8.07e-05	CbGpPWpGaD
Paliperidone—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	3.09e-05	8.06e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—CDKN1A—esophageal cancer	3.08e-05	8.03e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—PIK3CA—esophageal cancer	3.04e-05	7.94e-05	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	3.04e-05	7.93e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—ERBB2—esophageal cancer	3.04e-05	7.92e-05	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	3.03e-05	7.92e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—ERBB2—esophageal cancer	2.99e-05	7.8e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—MYC—esophageal cancer	2.98e-05	7.78e-05	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	2.98e-05	7.77e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—EP300—esophageal cancer	2.97e-05	7.74e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—EP300—esophageal cancer	2.95e-05	7.71e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—NOS3—esophageal cancer	2.94e-05	7.69e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	2.94e-05	7.69e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—EP300—esophageal cancer	2.93e-05	7.64e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—MYC—esophageal cancer	2.92e-05	7.62e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—EGFR—esophageal cancer	2.91e-05	7.61e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—NOS3—esophageal cancer	2.9e-05	7.56e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	2.89e-05	7.55e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—NOS3—esophageal cancer	2.89e-05	7.55e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—NOS3—esophageal cancer	2.89e-05	7.54e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PTGS2—esophageal cancer	2.88e-05	7.53e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—MYC—esophageal cancer	2.87e-05	7.5e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—CCND1—esophageal cancer	2.87e-05	7.49e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—EGFR—esophageal cancer	2.85e-05	7.45e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	2.84e-05	7.41e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—EGFR—esophageal cancer	2.81e-05	7.33e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	2.8e-05	7.32e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—CDKN1A—esophageal cancer	2.78e-05	7.25e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—CCND1—esophageal cancer	2.77e-05	7.24e-05	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	2.76e-05	7.22e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	2.76e-05	7.2e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—CCND1—esophageal cancer	2.76e-05	7.2e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—ERBB2—esophageal cancer	2.75e-05	7.19e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	2.75e-05	7.19e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CYP1B1—esophageal cancer	2.73e-05	7.11e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	2.71e-05	7.07e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—ERBB2—esophageal cancer	2.7e-05	7.06e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	2.7e-05	7.05e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CCND1—esophageal cancer	2.68e-05	7e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	2.68e-05	7e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	2.67e-05	6.96e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	2.65e-05	6.93e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—EP300—esophageal cancer	2.64e-05	6.9e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PTGS2—esophageal cancer	2.64e-05	6.9e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CCND1—esophageal cancer	2.64e-05	6.89e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	2.64e-05	6.88e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CDKN1A—esophageal cancer	2.59e-05	6.77e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—MYC—esophageal cancer	2.58e-05	6.75e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CYP19A1—esophageal cancer	2.56e-05	6.69e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CDKN1A—esophageal cancer	2.55e-05	6.67e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—EP300—esophageal cancer	2.55e-05	6.66e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MYC—esophageal cancer	2.55e-05	6.66e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—EP300—esophageal cancer	2.54e-05	6.63e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—PIK3CA—esophageal cancer	2.53e-05	6.6e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—EGFR—esophageal cancer	2.53e-05	6.6e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	2.51e-05	6.55e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—EGFR—esophageal cancer	2.49e-05	6.51e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—PIK3CA—esophageal cancer	2.48e-05	6.47e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—EP300—esophageal cancer	2.47e-05	6.44e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	2.47e-05	6.44e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—TP53—esophageal cancer	2.45e-05	6.39e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—PIK3CA—esophageal cancer	2.44e-05	6.36e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CCND1—esophageal cancer	2.43e-05	6.35e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—EP300—esophageal cancer	2.43e-05	6.34e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—EP300—esophageal cancer	2.4e-05	6.26e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—TP53—esophageal cancer	2.4e-05	6.26e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CCND1—esophageal cancer	2.39e-05	6.25e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CCND1—esophageal cancer	2.39e-05	6.24e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—TP53—esophageal cancer	2.36e-05	6.16e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	2.35e-05	6.15e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	2.34e-05	6.12e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—HMOX1—esophageal cancer	2.34e-05	6.1e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	2.32e-05	6.05e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	2.31e-05	6.03e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MYC—esophageal cancer	2.3e-05	6.01e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CREBBP—esophageal cancer	2.29e-05	5.99e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	2.27e-05	5.92e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—EGFR—esophageal cancer	2.25e-05	5.88e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ABCB1—esophageal cancer	2.24e-05	5.86e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—EP300—esophageal cancer	2.24e-05	5.85e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MYC—esophageal cancer	2.22e-05	5.8e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MYC—esophageal cancer	2.21e-05	5.77e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—EP300—esophageal cancer	2.2e-05	5.75e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—EP300—esophageal cancer	2.2e-05	5.74e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—EP300—esophageal cancer	2.2e-05	5.74e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—PIK3CA—esophageal cancer	2.19e-05	5.73e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—PIK3CA—esophageal cancer	2.18e-05	5.7e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	2.18e-05	5.69e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—EGFR—esophageal cancer	2.17e-05	5.68e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—PIK3CA—esophageal cancer	2.17e-05	5.65e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—EGFR—esophageal cancer	2.16e-05	5.65e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—EP300—esophageal cancer	2.16e-05	5.63e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MYC—esophageal cancer	2.15e-05	5.62e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TP53—esophageal cancer	2.12e-05	5.54e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MYC—esophageal cancer	2.12e-05	5.53e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	2.11e-05	5.5e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—EGFR—esophageal cancer	2.1e-05	5.49e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TP53—esophageal cancer	2.09e-05	5.47e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—EGFR—esophageal cancer	2.07e-05	5.41e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—NOS3—esophageal cancer	2.05e-05	5.36e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—EP300—esophageal cancer	2e-05	5.23e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—PIK3CA—esophageal cancer	1.95e-05	5.1e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MYC—esophageal cancer	1.95e-05	5.1e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MYC—esophageal cancer	1.92e-05	5.01e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MYC—esophageal cancer	1.92e-05	5e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—EGFR—esophageal cancer	1.91e-05	4.98e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TP53—esophageal cancer	1.89e-05	4.94e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	1.89e-05	4.93e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MYC—esophageal cancer	1.88e-05	4.91e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTGS2—esophageal cancer	1.88e-05	4.9e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—EGFR—esophageal cancer	1.88e-05	4.9e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	1.88e-05	4.9e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—EGFR—esophageal cancer	1.87e-05	4.89e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	1.84e-05	4.8e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—PIK3CA—esophageal cancer	1.83e-05	4.77e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TP53—esophageal cancer	1.83e-05	4.77e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TP53—esophageal cancer	1.82e-05	4.74e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—PIK3CA—esophageal cancer	1.8e-05	4.69e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PIK3CA—esophageal cancer	1.77e-05	4.63e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TP53—esophageal cancer	1.77e-05	4.61e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MYC—esophageal cancer	1.75e-05	4.56e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TP53—esophageal cancer	1.74e-05	4.54e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	1.71e-05	4.46e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	1.66e-05	4.33e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	1.63e-05	4.26e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	1.63e-05	4.25e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PIK3CA—esophageal cancer	1.63e-05	4.24e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TP53—esophageal cancer	1.6e-05	4.18e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	1.6e-05	4.17e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TP53—esophageal cancer	1.58e-05	4.12e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TP53—esophageal cancer	1.57e-05	4.11e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—EP300—esophageal cancer	1.56e-05	4.08e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TP53—esophageal cancer	1.54e-05	4.03e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.5e-05	3.92e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	1.48e-05	3.87e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TP53—esophageal cancer	1.43e-05	3.75e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—NOS3—esophageal cancer	1.34e-05	3.51e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.23e-05	3.21e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.16e-05	3.02e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—EP300—esophageal cancer	1.02e-05	2.67e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CA—esophageal cancer	7.56e-06	1.97e-05	CbGpPWpGaD
